Single User License
INR 136340
Site License
INR 272680
Corporate User License
INR 409020

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Hemophilia A-Pipeline Review, H1 2015

Hemophilia A-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Hemophilia A-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Hemophilia A-Pipeline Review, H1 2015', provides an overview of the Hemophilia A's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Hemophilia A

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Hemophilia A and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Hemophilia A products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Hemophilia A pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Hemophilia A

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Hemophilia A pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Hemophilia A Overview 8

Therapeutics Development 9

Pipeline Products for Hemophilia A-Overview 9

Pipeline Products for Hemophilia A-Comparative Analysis 10

Hemophilia A-Therapeutics under Development by Companies 11

Hemophilia A-Therapeutics under Investigation by Universities/Institutes 15

Hemophilia A-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Hemophilia A-Products under Development by Companies 20

Hemophilia A-Products under Investigation by Universities/Institutes 24

Hemophilia A-Companies Involved in Therapeutics Development 25

Alnylam Pharmaceuticals, Inc. 25

Amarna Therapeutics B.V. 26

Apitope International NV 27

AstraZeneca Plc 28

Bayer AG 29

Biogen, Inc. 30

BioMarin Pharmaceutical Inc. 31

Catalyst Biosciences, Inc. 32

Celtic Pharmaceutical Holdings L.P. 33

CSL Limited 34

DBV Technologies S.A. 35

Dimension Therapeutics, Inc. 36

Dong-A Socio Group 37

Emergent BioSolutions Inc. 38

EpiVax, Inc. 39

Expression Therapeutics LLC 40

F. Hoffmann-La Roche Ltd. 41

Green Cross Corporation 42

Inbiopro Solutions Pvt. Ltd. 43

Lentigen Technology, Inc. 44

Novo Nordisk A/S 45

Octapharma AG 46

OPKO Health, Inc. 47

Pharming Group N.V. 48

Promethera Biosciences S.A. 49

rEVO Biologics 50

Sangamo BioSciences, Inc. 51

Selecta Biosciences, Inc. 52

SK Chemicals Co., Ltd. 53

Spark Therapeutics, Inc. 54

The International Biotechnology Center (IBC) Generium 55

uniQure N.V. 56

Hemophilia A-Therapeutics Assessment 57

Assessment by Monotherapy Products 57

Assessment by Target 58

Assessment by Mechanism of Action 60

Assessment by Route of Administration 62

Assessment by Molecule Type 64

Drug Profiles 66

ALN-AT3-Drug Profile 66

antihemophilic factor (recombinant)-Drug Profile 67

antihemophilic factor (recombinant)-Drug Profile 69

antihemophilic factor (recombinant)-Drug Profile 71

antihemophilic factor (recombinant)-Drug Profile 72

antihemophilic factor (recombinant)-Drug Profile 73

antihemophilic factor (recombinant)-Drug Profile 74

antihemophilic factor (recombinant), fc fusion protein-Drug Profile 75

ATXF-8117-Drug Profile 77

AZ-10047130-Drug Profile 78

BAX-826-Drug Profile 79

BAX-855-Drug Profile 80

BAX-888-Drug Profile 82

BAY-1093884-Drug Profile 83

BAY-818973-Drug Profile 84

BMN-270-Drug Profile 86

coagulation factor VIIa (recombinant)-Drug Profile 87

concizumab-Drug Profile 89

CSL-689-Drug Profile 90

DA-3808-Drug Profile 92

damoctocog alfa pegol-Drug Profile 93

Deimmunized FVIII-Drug Profile 94

DTX-201-Drug Profile 95

eptacog alfa biosimilar-Drug Profile 96

ET-3-Drug Profile 97

Gene Therapy for Bleeding and Clotting Disorders-Drug Profile 98

Gene Therapy for Hemophilia A-Drug Profile 99

Gene Therapy for Hemophilia A-Drug Profile 100

Gene Therapy for Hemophilia A-Drug Profile 101

GNR-002-Drug Profile 102

HepaStem-Drug Profile 103

IBPH-001OC-Drug Profile 105

LG-889-Drug Profile 106

LR-769-Drug Profile 107

MOD-5014-Drug Profile 109

PF-05280602-Drug Profile 111

Protein for Hemophilia A-Drug Profile 113

Proteins for Hemophilia A-Drug Profile 114

Recombinant Protein for Hemophilia A-Drug Profile 115

Recombinant Protein to Replace Factor VIII for Hemophilia A-Drug Profile 116

Recombinant Protein to Replace Factor VIII for Hemophilia A-Drug Profile 117

RG-6013-Drug Profile 118

SEL-201-Drug Profile 119

SVF-VIIa-Drug Profile 120

turoctocog alfa pegol-Drug Profile 121

Hemophilia A-Recent Pipeline Updates 123

Hemophilia A-Dormant Projects 151

Hemophilia A-Discontinued Products 153

Hemophilia A-Product Development Milestones 154

Featured News & Press Releases 154

Appendix 162

Methodology 162

Coverage 162

Secondary Research 162

Primary Research 162

Expert Panel Validation 162

Contact Us 162

Disclaimer 163

List of Tables

Number of Products under Development for Hemophilia A, H1 2015 12

Number of Products under Development for Hemophilia A-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 15

Number of Products under Development by Companies, H1 2015 (Contd..1) 16

Number of Products under Development by Companies, H1 2015 (Contd..2) 17

Number of Products under Investigation by Universities/Institutes, H1 2015 18

Comparative Analysis by Late Stage Development, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Development, H1 2015 21

Comparative Analysis by Unknown Stage Development, H1 2015 22

Products under Development by Companies, H1 2015 23

Products under Development by Companies, H1 2015 (Contd..1) 24

Products under Development by Companies, H1 2015 (Contd..2) 25

Products under Development by Companies, H1 2015 (Contd..3) 26

Products under Investigation by Universities/Institutes, H1 2015 27

Hemophilia A-Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 28

Hemophilia A-Pipeline by Amarna Therapeutics B.V., H1 2015 29

Hemophilia A-Pipeline by Apitope International NV, H1 2015 30

Hemophilia A-Pipeline by AstraZeneca Plc, H1 2015 31

Hemophilia A-Pipeline by Bayer AG, H1 2015 32

Hemophilia A-Pipeline by Biogen, Inc., H1 2015 33

Hemophilia A-Pipeline by BioMarin Pharmaceutical Inc., H1 2015 34

Hemophilia A-Pipeline by Catalyst Biosciences, Inc., H1 2015 35

Hemophilia A-Pipeline by Celtic Pharmaceutical Holdings L.P., H1 2015 36

Hemophilia A-Pipeline by CSL Limited, H1 2015 37

Hemophilia A-Pipeline by DBV Technologies S.A., H1 2015 38

Hemophilia A-Pipeline by Dimension Therapeutics, Inc., H1 2015 39

Hemophilia A-Pipeline by Dong-A Socio Group, H1 2015 40

Hemophilia A-Pipeline by Emergent BioSolutions Inc., H1 2015 41

Hemophilia A-Pipeline by EpiVax, Inc., H1 2015 42

Hemophilia A-Pipeline by Expression Therapeutics LLC, H1 2015 43

Hemophilia A-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 44

Hemophilia A-Pipeline by Green Cross Corporation, H1 2015 45

Hemophilia A-Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 46

Hemophilia A-Pipeline by Lentigen Technology, Inc., H1 2015 47

Hemophilia A-Pipeline by Novo Nordisk A/S, H1 2015 48

Hemophilia A-Pipeline by Octapharma AG, H1 2015 49

Hemophilia A-Pipeline by OPKO Health, Inc., H1 2015 50

Hemophilia A-Pipeline by Pharming Group N.V., H1 2015 51

Hemophilia A-Pipeline by Promethera Biosciences S.A., H1 2015 52

Hemophilia A-Pipeline by rEVO Biologics, H1 2015 53

Hemophilia A-Pipeline by Sangamo BioSciences, Inc., H1 2015 54

Hemophilia A-Pipeline by Selecta Biosciences, Inc., H1 2015 55

Hemophilia A-Pipeline by SK Chemicals Co., Ltd., H1 2015 56

Hemophilia A-Pipeline by Spark Therapeutics, Inc., H1 2015 57

Hemophilia A-Pipeline by The International Biotechnology Center (IBC) Generium, H1 2015 58

Hemophilia A-Pipeline by uniQure N.V., H1 2015 59

Assessment by Monotherapy Products, H1 2015 60

Number of Products by Stage and Target, H1 2015 62

Number of Products by Stage and Mechanism of Action, H1 2015 64

Number of Products by Stage and Route of Administration, H1 2015 66

Number of Products by Stage and Molecule Type, H1 2015 68

Hemophilia A Therapeutics-Recent Pipeline Updates, H1 2015 126

Hemophilia A-Dormant Projects, H1 2015 154

Hemophilia A-Dormant Projects (Contd..1), H1 2015 155

Hemophilia A-Discontinued Products, H1 2015 156

List of Figures

Number of Products under Development for Hemophilia A, H1 2015 12

Number of Products under Development for Hemophilia A-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Products, H1 2015 21

Assessment by Monotherapy Products, H1 2015 60

Number of Products by Top 10 Targets, H1 2015 61

Number of Products by Stage and Top 10 Targets, H1 2015 61

Number of Products by Top 10 Mechanism of Actions, H1 2015 63

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 63

Number of Products by Top 10 Routes of Administration, H1 2015 65

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 65

Number of Products by Top 10 Molecule Types, H1 2015 67

Number of Products by Stage and Top 10 Molecule Types, H1 2015 67

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Alnylam Pharmaceuticals, Inc.

Amarna Therapeutics B.V.

Apitope International NV

AstraZeneca Plc

Bayer AG

Biogen, Inc.

BioMarin Pharmaceutical Inc.

Catalyst Biosciences, Inc.

Celtic Pharmaceutical Holdings L.P.

CSL Limited

DBV Technologies S.A.

Dimension Therapeutics, Inc.

Dong-A Socio Group

Emergent BioSolutions Inc.

EpiVax, Inc.

Expression Therapeutics LLC

F. Hoffmann-La Roche Ltd.

Green Cross Corporation

Inbiopro Solutions Pvt. Ltd.

Lentigen Technology, Inc.

Novo Nordisk A/S

Octapharma AG

OPKO Health, Inc.

Pharming Group N.V.

Promethera Biosciences S.A.

rEVO Biologics

Sangamo BioSciences, Inc.

Selecta Biosciences, Inc.

SK Chemicals Co., Ltd.

Spark Therapeutics, Inc.

The International Biotechnology Center (IBC) Generium

uniQure N.V.

Hemophilia A Therapeutic Products under Development, Key Players in Hemophilia A Therapeutics, Hemophilia A Pipeline Overview, Hemophilia A Pipeline, Hemophilia A Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com